MEDXF News and Press, Medexus Pharmaceuticals Inc From 06/01/23

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 1, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will be participating in the LD Micro Invitational XIII from June 6-8 2023. Event : LD Micro Invitational XIII Date : June ...

NCIB will commence on May 15, 2023 and is expected to continue through the debentures' October 2023 maturity date NCIB purchases will deleverage Medexus's balance sheet and lead to lower overall debt levels and reduced future debt service obligations in preparation for the debentures' October ...

ISPOR 2023 Presentation Shows 33% Lowered Costs with Gleolan Compared to Conventional White Light Surgery Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - May 9, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today presented data demonstrating a 33% cost savings with Gleolan&...

TORONTO and CHICAGO, April 18, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (TSX: MDP; OTCQX: MEDXF) is pleased to announce that company management will be participating in the 2023 Bloom Burton & Co. Healthcare Investor Conference from April 25 to 26, 2023. Event : 2023 Bloom B...

2023-04-11 07:40:26 ET Medexus Pharmaceuticals ( OTCQX:MEDXF ) reports preliminary revenue FY23 estimates to be $107-$108M, representing record annual revenue and a year-over-year increase of at least 39.5%. Annual revenue of $107-$108M implies total revenue between $28M and ...

TORONTO and CHICAGO, April 11, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (TSX: MDP; OTCQX: MEDXF) is pleased to announce preliminary revenue estimates for the company’s fourth fiscal quarter and full fiscal year ended March 31, 2023, and, in addition, is providing an ...

TORONTO and CHICAGO, March 22, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (TSX: MDP; OTCQX: MEDXF) is pleased to announce that the company has secured Canadian rights to commercialize terbinafine hydrochloride nail lacquer supplied by Polichem, an Almirall group company focused on...

TORONTO and CHICAGO, March 08, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (TSX: MDP; TSX: MDP.DB; OTCQX: MEDXF) today entered into a new senior secured credit agreement agented by BMO. The credit agreement provides for a US$35 million term loan facility and a US$3.5 ...

Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is a leader in innovative and rare disease treatment solutions with a strong North American commercial platform and a portfolio of proven best-in-class products. Their current focus is on the therapeutic areas of hematology, auto-immune diseases,...

TORONTO and CHICAGO, March 06, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (TSX: MDP; OTCQX: MEDXF) is pleased to announce that company management will be participating in the 35th Annual Roth Conference from March 12 to 14, 2023. Event : 35th Annual Roth Confer...